Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Bevacizumab (BEV, Avastin(®)) produces durable objective radiological responses of 20-26 %, median response durations of 16-18 weeks, and median overall survival (mOS) of 31-40 weeks. While the use of BEV is well-established, the lack of dose-response studies in glioblastoma (GBM) patients raises the question whether current dosing practice is optimal. As a result of differing approaches to BEV dosing that ranged from the FDA approved package insert dose of 10 mg/kg every 2 weeks to 7.5 mg/kg every 3-4 weeks, among physicians within Northern California Kaiser Permanente hospitals over 4+ years, we did an IRB-approved retrospective analysis of patients seen in Northern California Kaiser Permanente facilities and treated with BEV. Between September 1, 2008 and August 31, 2013, 181 patients received BEV for tumor progression/recurrence starting 2.6 weeks after completion of chemoradiation. The integrated BEV administered dose-week (AUCBEV) for all patients had a median AUCBEV of 3.6 mg·wk/kg). Maximum likelihood analysis found patients over 65 years did worse than younger patients (p = 0.004), women lived longer (p = 0.002), and patients treated below the AUCBEV did better than those treated above the median AUCBEV (p = 0.003). mOS for BEV starting 1 month after chemoradiation was 45 versus 68 weeks (p = 0.012) and BEV starting 3 months after chemoradiation was 40 versus 74 weeks (p = 0.0085). Dosing BEV at half the standard dose for progressive/recurrent GBM was at least equivalent to or, maybe better than standard dosing. Unexplained was the observation that females had longer OS with BEV than males.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the results of two retrospective studies have shown that low-dose bevacizumab (<3.6 mg/kg per week) in combination with chemoradiotherapy confers a greater survival benefit than high-dose bevacizumab (5 mg/kg per week) in patients with glioblastoma74–77”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [74]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
Levin, V. A., Bidaut, L., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S., Loghin, M., Gilbert, M. R., & Jackson, E. F. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.061 · Cited by 729
Self-citationFDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Effect of bevacizumab on radiation necrosis of the brain
Gonzalez, J., Kumar, A. J., Conrad, C. A., & Levin, V. A. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.10.010 · Cited by 415
Self-citationPseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 378
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Lu, J.-F., Bruno, R., Eppler, S., Novotny, W., Lum, B., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 350
Brandes, A. A., Tosoni, A., Spagnolli, F., Frezza, G., Leonardi, M., Calbucci, F., & Franceschi, E. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-008 · Cited by 284
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
Torcuator, R., Zuniga, R., Mohan, Y. S., Rock, J., Doyle, T., Anderson, J., Gutierrez, J., Ryu, S., Jain, R., Rosenblum, M., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9801-z · Cited by 188
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0260 · Cited by 173
Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging
Clarke, J. L., & Chang, S. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0035-4 · Cited by 170
Raizer, J. J., Grimm, S., Chamberlain, M. C., Nicholas, M. K., Chandler, J. P., Muro, K., Dubner, S., Rademaker, A. W., Renfrow, J., & Bredel, M. (2010) · Cancer · doi:10.1002/cncr.25462 · Cited by 149
Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
Wong, E. T., Gautam, S., Malchow, C., Lun, M. P., Pan, E., & Brem, S. S. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0037 · Cited by 148
Levin, V. A., Edwards, M. S. B., Wright, D., Seager, M. L., Tp, S., Jj, T., & Wilson, C. B. (1980) · PubMed · Cited by 141
Self-citationEvaluation of malignant glioma patients during the postirradiation period
Hoffman, W. F., Levin, V. A., & Wilson, C. B. (1979) · Journal of Neurosurgery · doi:10.3171/jns.1979.50.5.0624 · Cited by 136
Self-citationBevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wick, W., Weller, M., van den Bent, M. J., & Stupp, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9027 · Cited by 126
Chaskis, C., Neyns, B., Michotte, A., Ridder, M. D., & Everaert, H. (2009) · Surgical Neurology · doi:10.1016/j.surneu.2008.09.023 · Cited by 125
Bevacizumab Reverses Cerebral Radiation Necrosis
Wong, E. T., Huberman, M. S., Lu, X., & Mahadevan, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1866 · Cited by 99
Bevacizumab as Therapy for Radiation Necrosis in Four Children With Pontine Gliomas
Liu, A. K., Macy, M. E., & Foreman, N. K. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.032 · Cited by 84
Lubelski, D., Abdullah, K. G., Weil, R. J., & Marko, N. F. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1233-0 · Cited by 83
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
Piccioni, D. E., Selfridge, J. M., Mody, R. R., Chowdhury, R., Li, S., Lalezari, S., Wawrzynski, J. R., Quan, J., Zurayk, M., Chou, A. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou028 · Cited by 59
Pseudoprogression in Glioblastoma
Chamberlain, M. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4440 · Cited by 54
Rodriguez, M. A., DeJesus, A. Y., & Cheng, L. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1001 · Cited by 19
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
New Directions in Anti-Angiogenic Therapy for Glioblastoma
Wang, N., Jain, R. K., & Batchelor, T. T. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0510-y · Cited by 131
Tamura, R., Tanaka, T., Miyake, K., Yoshida, K., & Sasaki, H. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0284-x · Cited by 125
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Fu, M., Zhou, Z., Huang, X., Chen, Z., Zhang, L., Zhang, J., Hua, W., & Mao, Y. Q. (2023) · BMC Cancer · doi:10.1186/s12885-023-11043-6 · Cited by 109
Metadata
- Authors
- Levin, V. A., Mendelssohn, N. D., Chan, J., Stovall, M. C., Peak, S. J., Yee, J. L., Hui, R. L., & Chen, D. M.
- Affiliations
- Kaiser Permanente (US)
- Corresponding author
- Levin, Victor A.
- Venue
- Journal of Neuro-Oncology
- Published
- 2015-01-11
- Volume
- 122
- Issue
- 1
- Pages
- 145-150
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W2013247986
- Cited by
- 66
- References
- 29
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 5 · 2015: 6
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- bevacizumab, glioblastoma, dose-response relationship, overall survival, dose reduction, recurrent glioblastoma, chemoradiotherapy, sex differences, age effects, anti-VEGF therapy
- MeSH terms
- Bevacizumab, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Female, Follow-Up Studies, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Salvage Therapy, Disease Progression, Angiogenesis Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.